Kaitlyn D’Onofrio

DocwireNews

Rheumatoid arthritis (RA) patients with a history of inadequate response to at least one biologic may have good biologic persistence with the use of tocilizumab, according to a recent study. The findings were presented at European League Against Rheumatism (EULAR) 2019.&ldquo;The EULAR and [American College of Rheumatology] clinical guidelines recommend switching to a different disease-modifying antirheumatic drug (DMARD) when biologic-treated patients experience treatment failure or toxicity,&rdquo; the researchers wrote in their abstract, adding, &ldquo;Limited information is available regarding biologic therapy persistence across subcutaneously administered (SC) biologic agents in the real-world setting, as well as for comparative information on biologic persistence for SC biologics among patients with rheumatoid arthritis (RA) who are not naive to biologic treatment.&rdquo;Jennie H. Best, PhD, principal health economist with Genentech, Inc., who presented the findings, told DocWire News in an interview that the authors undertook this study because, &ldquo;Persistence is a proxy for effectiveness. Stakeholders, including payers, are interested in understanding how long patients persist on therapy.&rdquo;The researchers reviewed U.S. administrative claims data on adult RA patients initiating an SC biologic between Jan. 1, 2012, and June 30, 2017. Patients were eligible for inclusion if they had previously experienced failure with at least one biologic DMARD (bDMARD). The primary outcome was biologic persistence, which was defined as the number of days between initiating therapy and last supplied day of last fill. Researchers compared outcomes associated with tocilizumab use versus other biologics.<h2>Tocilizumab Comes Out on Top, Abatacept and Golimumab Close Behind</h2>A total of 10,301 patients (mean age, 51 years) were included in the study, with 12,704 bDMARD episodes. The most common bDMARD was adalimumab (n = 3,599); others included abatacept (n = 2,988), certolizumab (n = 982), etanercept (n = 2,760), golimumab (n = 745), and tocilizumab (n = 1,630).&ldquo;This study found that patients treated with subcutaneous tocilizumab had similar persistence on therapy to abatacept and golimumab, and significantly longer persistence than adalimumab, certolizumab, and etanercept,&rdquo; Dr. Best shared.Tocilizumab users had the highest adjusted median persistence days (333), followed by abatacept (320), golimumab (304), etanercept (289), adalimumab (280), and certolizumab (262).Among patients who had one year of data available, 55% initiated weekly tocilizumab and the rest initiated bi-weekly tocilizumab (n = 347); during the one-year period of follow-up, 33% of the bi-weekly initiators switched to weekly (mean time to switch, 177 days). At the end of one year, most patients (about 68%) were on weekly dosing.A limitation of the study was that it only included claims data, so it may not be generalizable to patient without insurance, Dr. Best said.The authors concluded in their abstract, &ldquo;Among patients with RA who previously used &ge;1 other biologic, tocilizumab-treated patients had similar or statistically significantly better biologic persistence compared with other biologics.&rdquo;

Jordana Jampel

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Latest News

Tocilizumab Effective After Previous Biologic DMARD Failure

Rheumatology

Rheumatoid arthritis (RA) patients with a history of inadequate response to at least one biologic may have good biologic persistence with the use of tocilizumab

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe